Sales of SGLT-2 diabetes drugs surpassed 150 billion won

Last year, The SGLT-2 inhibitor market sales was 150.1 billion won ( ↑17.2% )

Forxiga and Xigduo market share 52.9%

Sales of SGLT-2 inhibitor-based diabetes treatments exceeded 150 billion won for the first time last year.

 

The SGLT-2 inhibitor market, including Forxiga and Jardiance, continues to grow at double digits every year.

 

◆ Sales of SGLT-2 inhibitors have increased five times in the past five years According to UBIST, a pharmaceutical market research firm on the 21st, the total amount of outpatient prescriptions for SGLT-2 inhibitors last year was 150.1 billion won, up 17.2% from the previous year.

 

Sales of SGLT-2 inhibitors in Korea, which amounted to 28.6 billion won in 2016, have more than tripled in the past five years.

 

The market size of SGLT-2 inhibitors has grown year by year.

 

It rose from 50.1 billion won in 2017 to 70.3 billion won (40%) in 2018, followed by 96.9 billion won (37.8%) in 2019.

 

The following year, it achieved 127.9 billion won (32%) in 2020.

 

This growth is expected to continue for the time being.

 

Both Forxiga and Jardiance, SGLT-2 inhibitors, are likely to increase their prescription performance in the future as their indications expand to patients with full heart failure in addition to diabetes treatment.

 

SGLT-2 plays a role in reabsorbing glucose from urine into blood.

 

SGLT-2 inhibitors are mechanisms that inhibit this reabsorption action to prevent glucose from entering the bloodstream and release it into urine.

 

◆SGLT-2 inhibitors such as Forxiga and Jardiance lead the growth The leading items in the domestic SGLT-2 inhibitor market are AstraZeneca's Forxiga and Jardiance.

 

Last year, Sales of AstraZeneca's Forxiga and Xigduo recorded 79.5 billion won.

 

The domestic market share alone is 52.9%.

 

By product, Forxiga's outpatient prescription amount was 42.6 billion won, up 12% from the previous year.

 

During the same period, Xigduo recorded 36.9 billion won, up 21.3%.

 

It is analyzed that AstraZeneca got the preemptive effect when it first introduced Forxiga in Korea in 2014.

 

The joint sale with domestic companies from the beginning of entering the market is also believed to have affected the increase in performance.

 

AstraZeneca started co-selling with CJ Healthcare (currently HK inno.N) from the beginning of its launch.

 

Since March 2018, it has been jointly selling with Daewoong Pharmaceutical.

 

Jardiance and Jardiance Duo of Beringer Ingelheim and Lilly are closely chasing Forxiga.

 

Last year, Jardiance achieved 40.9 billion won in outpatient prescription performance, up 10.8%.

 

During the same period, Jardiance Duo also rose 46.7% to 24.5 billion won.

 

The performance of these two items is 65.3 billion won, with 43.5% market share.

 

Jardiance was released in 2016, two years later than Forxiga in the domestic SGLT-2 inhibitor market.

 

Although it is generic, it is evaluated that it is acting as a positive factor in expanding prescription performance by proving the effect of reducing cardiovascular mortality through clinical trials.

 

Astellas' Suglat and MSD's Steglatro's prescription performance was poor.

 

Suglat's outpatient prescription amount stood at 3.5 billion won last year, similar to the previous year.

 

Suglat has been in charge of distribution, marketing, and sales since April 2018.

 

At that time, a synergy effect was expected when Handok, which had diabetes treatments such as Tenelia, introduced Suglat, but its performance was not good.

 

MSD's Steglatro rather reduced prescription performance.

 

Last year, Steglatro's outpatient prescriptions fell 21.8% from the previous year.